PET/CT in Non-Hodgkin Lymphoma: An Update

Semin Nucl Med. 2023 May;53(3):320-351. doi: 10.1053/j.semnuclmed.2022.11.001. Epub 2022 Dec 14.


Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative disorders characterized by different clinical courses, varying from indolent to highly aggressive. 18F-FDG-PET/CT is the current state-of-the-art diagnostic imaging, for the staging, restaging and evaluation of response to treatment in lymphomas with avidity for 18F-FDG, despite it is not routinely recommended for surveillance. PET-based response criteria (using five-point Deauville Score) are nowadays uniformly applied in FDG-avid lymphomas. In this review, a comprehensive overview of the role of 18F-FDG-PET in Non-Hodgkin lymphomas is provided, at each relevant point of patient management, particularly focusing on recent advances on diffuse large B-cell lymphoma and follicular lymphoma, with brief updates also on other histotypes (such as marginal zone, mantle cell, primary mediastinal- B cell lymphoma and T cell lymphoma). PET-derived semiquantitative factors useful for patient stratification and prognostication and emerging radiomics research are also presented.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma, Large B-Cell, Diffuse*
  • Lymphoma, Non-Hodgkin* / diagnostic imaging
  • Lymphoma, Non-Hodgkin* / therapy
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography


  • Fluorodeoxyglucose F18